Issue No. 001 · Published Friday, October 16, 2026 · Edited by Dr. Phillip Alvelda
Welcome to the very first issue of Health AI Docket, and thank you for being here at the start.
AI is transforming health care faster than the rules around it can settle. Each week brings a new FDA paper, a state law, a CMS pilot or a court fight, and keeping up can feel like a second job. We started this newsletter to make it a five-minute read instead.
Health AI Docket is for the people who have to act on these changes: health system leaders, clinicians, digital health founders, compliance and regulatory teams, and the investors backing them. Every week we cover FDA decisions and guidance on AI-enabled devices, comment deadlines worth knowing about, CMS and Federal Register notices, and new state laws on clinical AI and prior authorization.
Our promise is simple. Every item links to its primary source, so you can check it yourself. We summarize; we don't spin. This is not legal advice, so read the source before you act.
We're glad you're here. Let's get into it.
FDA generative-AI device comments close Monday, Oct 19. Docket FDA-2026-N-7874.
In this issue
- FDA asks for input on regulating generative AI devices (comments due Oct 19)
- CDRH's FY2027 guidance agenda puts AI at the top
- By the numbers: 1,600+ AI-enabled devices authorized
- California: a licensed clinician must make the final call (effective Jan 1, 2027)
- Prior authorization: states say AI can't be the only reason for a denial
1. FDA asks for input on regulating generative AI devices (comments due Oct 19)
FDA's Digital Health Center of Excellence released a discussion paper, Considerations for the Regulation of Generative AI-Enabled Medical Devices. It floats a two-axis risk framework, a "competency assessment" approach to premarket evaluation (non-clinical benchmarking plus clinical confirmation), risk-proportionate postmarket monitoring, and questions about foundation models and agentic systems. FDA says the paper is not draft or final guidance.
Why it matters: this is the earliest look at how FDA may evaluate LLM-based devices. Deadline: comments go to docket FDA-2026-N-7874 on Regulations.gov by October 19, 2026.
Sources: FDA discussion paper · FDA press release
2. CDRH's FY2027 guidance agenda puts AI at the top
On October 1, CDRH published its FY2027 guidance priorities. Top of the A-list: finalizing the January 2025 draft on lifecycle management for AI-enabled device software functions. Also listed: a new draft on generative-AI conversational devices for mental health disorders. Comments on the priority lists are due November 30, 2026 (docket FDA-2012-N-1021).
Source: RAPS Regulatory Focus
3. By the numbers: 1,600+ AI-enabled devices authorized
FDA's AI-enabled device list now counts more than 1,600 devices authorized for US marketing as of September 2026. The final PCCP guidance (August 2025) remains the main route for pre-planned model updates without a new submission for each change.
Sources: FDA AI-enabled devices page · FDA PCCP final guidance
4. California: a licensed clinician must make the final call (effective Jan 1, 2027)
On September 30, California signed AB 1979, which says no clinical decision may rest solely on a clinical decision support system's output, and SB 503, which requires CDS developers to identify and mitigate foreseeable bias and requires users to monitor on an ongoing basis. Both take effect January 1, 2027. Meanwhile, on October 5 Utah expanded its AI regulatory sandbox into health care, with pilots in which physician review of AI-generated prescriptions is scheduled to decrease over time.
Source: Telehealth.org
5. Prior authorization: states say AI can't be the only reason for a denial
Alabama SB 63 took effect October 1, 2026: insurers can't base coverage decisions solely on AI, must disclose AI use, and must certify annually that their tools don't rely on group datasets. Similar laws passed this year in Iowa, Washington, Colorado, Maryland and Utah. At the federal level, CMS's WISeR AI prior-auth model (live in six states since January) faces a GAO opinion that it is a "rule" under the Congressional Review Act, and a House appropriations amendment to defund it in FY2027.
Sources: Holland & Knight · Becker's Payer Issues · Manatt Health AI Policy Tracker
Dates to watch
- Oct 19: FDA GenAI discussion-paper comments due (FDA-2026-N-7874)
- Nov 30: CDRH FY2027 guidance-agenda comments due (FDA-2012-N-1021)
- Jan 1, 2027: California AB 1979 and SB 503 take effect
Get involved
Tips, contributions and corrections. Spotted a rule, ruling or deadline we should cover, or something we got wrong? Reply to this email or write to [email protected]. We fix errors openly.
Sponsorship. Want to reach health-AI decision makers? Email [email protected] with the subject "Sponsorship". Sponsors are always clearly labeled and never influence our coverage.
Summaries of public regulatory information; not legal, regulatory or medical advice. Read the primary source before you act. Subscribe free to get each issue by email.